Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that UroGen Pharma Ltd. made materially false and/or misleading statements and/or failed to disclose that:
On May 16, 2025, the FDA stated: “Given that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.”
Following this news, the price of the Company’s stock dropped on the same day.
In order to be eligible to join the URGN class action lawsuit, you must have incurred a loss on shares of UroGen Pharma Ltd. purchased during the class period listed above.
TOP
